Oncolytics Biotech, Inc (ONCY) saw an uptrend of 5.39% in the recent trading with $0.61 being its most recent. The current price level -60.26% lower than the highest price of $1.53 marked by the stock while trading over the past 52-weeks, whereas it is 86.62% higher than the lowest price of $0.33 the company dropped to over past 52-weeks. The latest news story on ONCY appeared in (PR Newswire) under the title “As Public Cancer Funding Wavers, Oncology’s Brightest Breakthroughs Are Coming From Industry”.
Squeezing the time span to 30 day period shows us the stock is currently trading -1.12% below one month high and is +86.62% above of the lowest during that time. Looking into the simple moving average, Oncolytics Biotech, Inc (ONCY)’s stock stands at a SMA-50 of $0.4962 while that of 5-day is reading $0.5259.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and ONCY’s SMA-200 as of now is $0.7947.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 1 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.40 for the stock.
Oncolytics Biotech, Inc Earnings – What Happened With ONCY
Coming around sales and income figures on ONCY Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
ONCY – Oncolytics Biotech, Inc Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 86.42 million. ONCY does have institutional investors; and they hold 10.75% of the stock.
Oncolytics Biotech, Inc – Insider Activity and Holdings
As on 2024-06-30, INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC was the top most holder in Oncolytics Biotech, Inc (NASDAQ:ONCY) with an ownership of 0.2 million shares of the company or 0.2607 of the stake worth $0.2 million. The filing also reveals SEEDS INVESTOR LLC as the second largest holder in the company with a control over 0.2496 of the outstanding shares. Its stake is worth $0.19 million for having 0.19 million shares in hand.
MORGAN STANLEY also came holding a key position in the company during the recent quarter and it now holds 0.182 of the outstanding shares. With this there are now 53.0 institutions which have possession in ONCY’s shares.
Currently, the stock has been recommended as Strong Buy by 1 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.40 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Oncolytics Biotech, Inc has a debt to equity ratio of 0.15.
Technical Analysis of Oncolytics Biotech, Inc (NASDAQ:ONCY) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Oncolytics Biotech, Inc (ONCY), we notice that the stock’s 20-day average volume is at 1,384,910 shares and 50% of short term indicators are suggesting the stock as Sell. Medium term indicators at an average of 50% are spotting the stock at Sell with its 50-day average volume of 750,388 shares. And to end, ONCY’s 100-day average volume is 608,202 shares with 50% of the long-term indicators pointing towards Sell for the stock.
